U.S. FDA Accepts Regulatory Submission for Tanezumab, an NGF inhibitor, for the Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Ost

U.S. FDA Accepts Regulatory Submission for Tanezumab, an NGF inhibitor, for the Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis https://t.co/9NsESTnn4S

Links:

U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Clas… http://bit.ly/2Iec3q5

RheumNow

Mar-02-2020

Topics

Do you get our email newsletter?